The present invention provides an industrial method production of amorphous posaconazole. The present invention also relates to a method for production of the posaconazole via and novel crystalline forms of posaconazole intermediate. More particularly the present invention relates to novel crystalline forms of posaconazole intermediate and methods for production of novel crystalline forms of posaconazole intermediate represented by the following structural formula III Which is key intermediate in the production of posaconazole. The present invention also provides for the one pot process for the preparation of amorphous posaconazole using novel crystalline forms of benzyl posaconazole.

##STR00001##

The present application relates to polymorphs of Compound A:

##STR00001##

or a stereoisomer thereof, and methods of preparation and use thereof.

A method for the extraction and isolation of the terpene and isoprenoid compounds from plant material, followed by a centrifugal force induced selective crystallization of isoprenoids resulting in a separation of terpene and isoprenoid fractions. This this method is suitable for the extraction of cannabinoids from Cannabis and the enrichment tetrahydrocannabinolic acid and reduction of tetrahydrocannabinol in an extract. The purity of tetrahydrocannabinolic acid resulting from centrifugal crystallization is such that dissolution and selective recrystallization of tetrahydrocannabinolic acid is possible resulting in >99.9% pure tetrahydrocannabinolic acid, w/w.

The pharmaceutical industry is highly regulated to ensure the safety, efficacy, and quality of medicines and drug discolouration is one of the leading causes for drug recall. An object of the present invention is to provide an improved method of manufacturing cannabinoids for use in pharmaceuticals that is both stable and substantially pure. Such use of stable and substantially pure cannabinoids in pharmaceuticals will improve patient compliance to medication. The main steps of the method are decarboxylation, extraction, winterization and crystallisation.

A crystallization column and a crystallization method. The crystallization column comprises an upper head (1), a tower body (2) and a lower head (3), wherein a crystallization section (11) is provided with a tray (14); and the tray (14) comprises a tray plate (15) and a plurality of lower crystallization members (17). The top end of the lower crystallization member (17) can form a movable connection with the tray plate (15), so that the two adjacent lower crystallizing members (17) are capable of oscillating collisions. The tray (14) may also comprise a plurality of upper crystallization members (21) extending upwardly from the upper surface of the tray plate (15).

Process for producing a suspension by precipitation of a solid from a solution, wherein at least two solutions of salts are combined with one another in a stirred vessel so as to form a sparingly soluble solid, where portions of suspension are taken off continuously or discontinuously, the portions taken off in this way are processed in a combination of two separation apparatuses, where gas is separated off in a first separation apparatus which is selected from liquid-gaseous separation apparatuses, and mother liquor is separated off from precipitated sparingly soluble solid in a second separation apparatus selected from solid-liquid separation apparatuses, and the mother liquor is taken off, and the solid which has been separated off or enriched in this way is returned to the reaction mixture.

Stable liquid formulations dominant in cannabidiol (CBD) can be manufactured by a sequential process of purification to create a formulation that does not crystallize under a variety of storage and use conditions, and without the use of potentially harmful additives. For example, the formulation may be used in vaporization devices (i.e., electronic cigarettes) that typically require formulations to remain in a non-crystalline, non-solid, or non-partially solid state. The liquid formulations dominant in CBD may further contain other phytocannabinoids, including, but not limited to, tetrahydrocannabinol (THC), cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), and cannabidivarin (CBDV) in higher concentrations than unrefined and refined cannabis extracts obtained via existing methods.

Disclosed herein are plinabulin polymorphs, compositions, their use and preparation as therapeutic agents. In particular, some embodiments relate to plinabulin monohydrate in a crystalline form.

The present invention refers to new amorphous and crystalline solid forms of desvenlafaxine, also known as O-desmethylvenlafaxine or desmethylvenlafaxine, and to its salts, solvates, hydrates and polymorphs thereof, as well as to their use in the manufacture of a pharmaceutical composition useful in the treatment of depression and/or as a selective serotonin and norepinephrine reuptake inhibitor and also in menopause-associated vasomotor disorders.

Disclosed herein are plinabulin polymorphs, compositions, their use and preparation as therapeutic agents. In particular, some embodiments relate to plinabulin monohydrate in a crystalline form.